The market – the future starts now

Cannabis is cultivated and exported worldwide. In Europe, cannabis is mainly cultivated in Germany, the Netherlands and Italy, and cultivation often takes place in so-called indoor facilities. Due to special cultivation conditions, higher crop yields are achieved than in open field cultivation. The use of cannabis for medicinal purposes dates back a long way, especially in India and Middle Eastern countries.

However, in the 20th century, cannabis was gradually replaced by other medications. Eventually, the medicinal use of cannabis declined rapidly following the onset of worldwide prohibition. Since 2017, cannabis preparations have been marketable for the manufacture of medicinal products in Germany as well as several countries in Europe, and finished medicinal products containing cannabis are available on prescription.

Show more

Market development of medicinal cannabis in Europe by product

in millions of Euros

Market maturity and legalisation process in Europe

‘Medicinal cannabis
is the market of the future worth billions!’

Peter Thiel, billionaire and investor

The legalisation of cannabis in Switzerland has had majority support for some time. According to a poll in July, two thirds of the population voted for the liberalisation of cannabis – with strict controls.

In the middle of October, the responsible Committee of the Council of States, i.e. the body that represents the cantons in the Swiss parliament, gave the green light by a clear majority for the sister committee in the National Council to comprehensively reregulate cultivation, production, trade and consumption. Accordingly, the Narcotics Act will be amended in Switzerland to simplify the distribution of cannabis for medicinal purposes and to allow its export.

This has created the basis for a regulated – and legal – cannabis market in Switzerland with great growth potential. MediCrops focuses on the THC-based medicinal cannabis sector with various product formats, such as patented ready-to-use medicines, inhalants and extracts from our own production for the pharmaceutical industry, among others. We clearly distinguish ourselves from stimulants such as intoxicants and food supplements (CBD). Our target market is Europe with a focus on Germany, Austria and Switzerland (German-speaking countries) and the development of an efficient distribution network throughout Europe.

Show more